Unanticipated efficacy of SARS-CoV-2 vaccination in older adults

The rapidity with which vaccines against COVID-19 have been developed and tested is unprecedented. As classically the case with randomized clinical trials, many studies excluded older adults. However, given the early realisation that senior citizens were most highly susceptible to COVID, older individuals have been included in licensing trials under these unusual conditions. The recently published results from the Comirnaty Vaccine (BNT162b) trial unexpectedly documented that vaccine efficacy was equally exceptionally high in older and younger adults. These extremely encouraging trial results with a neoantigen vaccine may suggest the beginning of a paradigm shift in our view of the impact of immunosenescence on vaccination against novel infectious diseases.

Automated summary

The rapid development and testing of COVID-19 vaccines have shown high efficacy in older adults, potentially leading to a paradigm shift in understanding the impact of immunosenescence on vaccination against novel infectious diseases.